Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

about

Ginseng Compatibility Environment Attenuates Toxicity and Keeps Efficacy in Cor Pulmonale Treated by Fuzi Beimu Incompatibility Through the Coordinated Crosstalk of PKA and Epac Signaling Pathways.

P2860

Q55497267-241064B3-6252-45B7-A488-8FE25681C276

P2860

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

Item

http://www.wikidata.org/entity/Q47966525

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

@en

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

@nl

type

Item

label

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

@en

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

@nl

prefLabel

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

@en

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

@nl

P1476

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

@en

P2093

Thomas J Monaco

http://www.w3.org/2001/XMLSchema#string

P2860

β(2) -adrenoceptor agonists: current and future direction

Clinical and economic impact of non-adherence in COPD: a systematic review

Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema

Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma

The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation

ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

P304

285-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14728214.2017.1367382

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicola A Hanania

P577

2017-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28868931

http://www.w3.org/2001/XMLSchema#string

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

about

P2860

P2860

Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698